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In spite of the controversy
surrounding human cloning,
British scientists were given a
licence last month to create
Europe’s first cloned human
embryos for strictly controlled
research. The licence was granted
to a team in Newcastle upon Tyne,
placing the country at the
forefront of worldwide efforts to
create a revolutionary generation
of medical treatments.
Scientists such as Ian Wilmut,
who cloned Dolly the sheep,
welcomed the news as the first
step in an effort to provide new
insights into illness and ways to
grow a patient’s own cells to treat
a vast range of diseases, from
Alzheimer’s to Parkinson’s.
But the decision was
condemned by pro-life
campaigners as tragic and
frightening. It marked the
manipulation, exploitation and
trivialisation of human life, they
said.
The Human Fertilisation and
Embryology Authority gave the
Newcastle team permission to
study how to clone early human
embryos efficiently and use them
as a source of stem cells with the
potential to develop into any type
for medical treatments and to
understand disease. The authority
emphasised: “Stem cells created
under this licence will be used for
research only.” It is the first time
such work has been approved in
Europe.
When the application was
submitted in February by Alison
Murdoch, of the Newcastle NHS
Fertility Centre, and Miodrag
Stojkovic, of Newcastle University,
the aim was to develop a
treatment for diabetes and to
reach a point where a type I
diabetic’s tissue could be grown
for transplant. But the image of
therapeutic cloning as a potential
cure received a dent when it
emerged that the overall aim of
the original application was
questioned by a committee of the
Fertilisation and Embryology
Authority. Because it raised legal
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issues that could be seized upon
by pro-life campaigners, the team
has dropped the aim for the time
being.
Research into therapeutic
cloning is at such an early stage
that almost every step of the
process is fraught with difficulty.
Cloning is so inefficient that
typically hundreds of eggs are
used trying to create one embryo
from which stem cells can then be
harvested. Korean scientists who
recently reported the first stem-
cell line from cloned human
embryos said they used more
than 200 eggs.
Denise Faustman, a researcher
in diabetes at Harvard Medical
School, said a ‘paradigm shift’ in
diabetes research had occurred
that placed more emphasis on
alternative approaches. Pro-life
groups, such as Comment on
Reproductive Ethics (Core), said
that stem cells from a cloned
embryo of a diabetic patient may
suffer from the same disorder.
They cite evidence from studies
in mice that the stem cells may
proliferate out of control and
provoke immune reactions. For
‘pro-life’ campaigners, the
inefficiency of cloning is a
serious impediment. Patrick
Cusworth, of Life, says that if
350,000 people in Britain have
type I diabetes, then with today’s
success rates it would take 35
million eggs to treat them all
using therapeutic cloning. That
compares with 930,000 embryos
created in fertility clinics since
1990.
Core said it was taking legal
advice on the legality of the
cloning licence. Josaphine
Quintavalle, a spokesperson, also
questioned whether there was a
conflict of interest in the role of
Murdoch as head of the fertility
unit that provides eggs for cloning
and her role in submitting the
application to use the eggs.
Murdoch said: “We have
overwhelming support from senior
scientists and clinicians from all
over the world and many letters
from patients who may benefit
from the research.
“Realistically, we have at least
five years of further laboratory
work to do before we move into
clinical trials but this could be
reduced if we receive additional
funding.”
The British government is
considering a raft of policies to
bolster the economies of northern
England, which may include plans
for northern universities. The
outcome may see Newcastle
becoming a global centre for
researching stem cell therapies.
Stojkovic said he was surprised
and pleased that the licence had
been granted. He said:
“Newcastle is now the national
front-runner in this area of
research but pressure is mounting
in America for its scientists to be
allowed to do this work. If we are
to stay at the cutting edge, we
must obtain further financial
backing, or, as has happened
before, Britain will lose out.”
The decision means that the
Newcastle team could become
only the second in the world to
carry out human cloning
successfully after the recent claim
by Korean scientists.
Suzi Leather, the chairman of
the Human Fertilisation and
Embryology Authority, said: “After
careful consideration of all the
scientific, ethical, legal and
medical aspects of the project,
the licence committee agreed to
grant an initial one-year research
licence to the Newcastle Centre
for Life.
“In Britain, research on human
embryos is permitted only for
certain purposes. The purpose of
this research is to increase
knowledge about the
development of embryos and
enable the knowledge to be
applied in developing treatments
for serious disease. This research
is preliminary. It is not aimed at
specific illnesses.”
At Newcastle, Murdoch and
Stojkovic now have the chance to
see just how difficult human
therapeutic cloning will be. “It
could be that it works in humans
straight away, or it could turn out
to be much tougher than doing it
in animals,” says Murdoch. “There
are big hurdles, but none are
insurmountable. If you think back
25 years when IVF first started, if
we’d given up when the first few
attempts didn’t work, we’d never
have the routine service we have
now.”
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What attracted you to biology? It
was the infectious (if naïve)
enthusiasm of my college physics
lecturer, Richard Feynman. He was
full of ideas about how physics
could account for the physiology
and evolution of plants and animals
— everything from the transport of
water in trees to the spacing of
ommatidia in compound eyes. The
sections on polarized light and
magnetic fields turned out to be
very useful.
Equally important was my
chance encounter with Konrad
Lorenz’s King Solomon’s Ring. This
led me to take Seymour Benzer’s
behavioral biology course, which
lured me into the dance-language
controversy. In 1946, Karl von
Frisch reported that honey bees
have an abstract language — a
communication system which
encodes the distance, direction
and quality of a food source. The
dances do occur and (with enough
averaging) the location can be
inferred, but an American group
had just shown that conventional
olfactory cues might explain
everything; the correlations were,
in their view, an artifact. Designing
a test that pitted odor against
location was an exhilarating
challenge. The dance is also a
read-out of what foragers have
extracted in the way of navigation
cues. And then they are content to
visit a feeder every few minutes,
cheerfully allow themselves to be
marked or moved, have the floral
stimuli modified between or even
during trips, and in nearly every
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